2024
O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma
Hoppe B, Castellino S, Pei Q, Charpentier A, Mailhot-Vega R, Roberts K, Parikh R, Flampouri S, Kelly K, Hodgson D. O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma. International Journal Of Particle Therapy 2024, 11: 100032. DOI: 10.1016/j.ijpt.2024.100032.Peer-Reviewed Original Research
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphomaNCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapyRadiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original Research
2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 1218-1230. PMID: 34781267, DOI: 10.6004/jnccn.2021.0054.Peer-Reviewed Original ResearchConceptsB-cell lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyB-cell non-Hodgkin lymphomaCAR T-cell therapyB-cell receptor pathwayLarge B-cell lymphomaNCCN Guidelines InsightsRelapsed/refractoryT-cell therapyNon-Hodgkin lymphomaNovel treatment optionsMantle cell lymphomaAntibody-drug conjugatesR diseaseTherapy optionsTreatment optionsCell lymphomaFollicular lymphomaSmall molecule inhibitorsLymphomaMolecular pathogenesisReceptor pathwayMolecule inhibitorsTherapyPediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage J, Hiniker S, Armenian S, Benya E, Bobbey A, Chang V, Cooper S, Coulter D, Cuglievan B, Hoppe B, Isenalumhe L, Kelly K, Kersun L, Lamble A, Larrier N, Magee J, Oduro K, Pacheco M, Price A, Roberts K, Smith C, Sohani A, Trovillion E, Walling E, Xavier A, Burns J, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 733-754. PMID: 34214968, DOI: 10.6004/jnccn.2021.0027.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaClassic Hodgkin lymphomaHodgkin's lymphomaNCCN Clinical Practice GuidelinesClinical practice guidelinesCurrent treatment regimensNCCN guidelinesRefractory settingSystemic therapyCurable formTreatment regimensPrinciples of pathologyDiagnostic evaluationLate effectsPractice guidelinesRadiation therapyTreatment efficacyLymphomaTherapyTreatmentGuidelinesRegimensWorkupCancerStaging
2020
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
Ballas LK, Metzger ML, Milgrom SA, Advani R, Bakst RL, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Constine LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia & Lymphoma 2020, 62: 1057-1065. PMID: 33274673, DOI: 10.1080/10428194.2020.1852559.Peer-Reviewed Original ResearchConceptsNodular lymphocyte predominant Hodgkin lymphomaHodgkin's lymphomaAmerican Radium Society Appropriate Use CriteriaLymphocyte predominant Hodgkin lymphomaAppropriate use criteriaMultidisciplinary expert panelPredominant Hodgkin lymphomaClassical Hodgkin lymphomaRare lymphomaClinical variantsAmerican Radium SocietyConsensus recommendationsGuideline developmentRadiation oncologistsLymphomaStrong recommendationsCompelling dataConsensus methodologyUse criteriaExpert panelExpert opinionExecutive summaryLiterature reviewGuidelinesPatientsPatterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group
Parikh R, Hoppe B, Hodgson D, McCarten K, Pei Q, Cho S, Schwartz C, Cole P, Kelly K, Roberts K. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s36-s37. DOI: 10.1016/j.ijrobp.2020.07.2140.Peer-Reviewed Original Research
2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFL
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2014
ACR appropriateness Criteria® pediatric Hodgkin lymphoma
Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer 2014, 61: 1305-1312. PMID: 24616347, DOI: 10.1002/pbc.24983.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAppropriateness of imagingACR Appropriateness CriteriaExpert panelMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesCommon clinical scenariosSpecific clinical conditionsCurrent medical literaturePotential long-term effectsCurable malignancyExpert medical opinionClinical variantsClinical conditionsLong-term effectsAmerican CollegeClinical careTherapy needTreatment approachesGuideline developmentClinical scenariosLymphoma
2013
ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology 2013, 27: 786-94. PMID: 24133827.Peer-Reviewed Original ResearchConceptsIndolent lymphomaAppropriateness of imagingOutcomes of patientsMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsPeer-reviewed journalsPrognostic factorsTreatment optionsAppropriateness CriteriaTreatment decisionsClinical conditionsAmerican CollegeGuideline developmentMedical literatureRadiation guidelinesConsensus methodologyLymphomaExpert panelRadiation dosePatientsRadiation techniques